Jump to content

Gabriella Gobbi

Add links
From Wikipedia, the free encyclopedia

Gabriella Gobbi is an Italo-Canadian psychiatrist and neuroscientist whose research explores novel treatments for mental health disorders.[1][2][3] Gobbi is a professor at McGill University's Department of Psychiatry and a Canada Research Chair (Tier 1) in Therapeutics for Mental Health.[2][4]

Research career

[edit]

In 1991, Gobbi completed a Doctor of Medicine degree, and specialized in Psychiatry and Psychotherapy (1995) at the Catholic University of Rome in Italy and later obtained a PhD in neuroscience under the supervision of Gianluigi Gessa. [1]

Scientific contributions

[edit]

Psychedelics for anxiety

[edit]

Gobbi's research has shown that regular administration of low doses of LSD (lysergic acid diethylamide) reduces anxiety, through mechanisms similar commonly prescribed classes of antidepressants and selective serotonin reuptake inhibitors (SSRIs), and that LSD signaling also activates the mTOR signalling pathway.[5][6][7][8]

Cannabis and association with depression in adolescence

[edit]

Dr. Gobbi's lab discovered that adolescent cannabis consumption induces depression-like behavior in animals.[9][10] Upon finding that there is a link between depression and long-term cannabis consumption in young people,[11] Gobbi engaged widely with stakeholders and the media, ultimately resulting in a change in the legal age of cannabis consumption in Quebec from 18 to 21, and her receiving the 2020 Principal's Prize for Public Engagement through Media (Established Academics category) from McGill University.[12]

Melatonin MT2 receptor agonists for pain and insomnia

[edit]

Even if melatonin was isolated more than 60 years ago, the roles of GPCR melatonin receptors (named MT1 and MT2) remained unknown. Her lab discovered that the MT1 and MT2 receptors have very specialized functions: while the MT1 activates REM sleep, the MT2 receptor acts on NREM sleep.[13][14] Her lab also synthesized and developed novel selective MT2 receptors partial agonists for the treatment of insomnia[15] and neuropathic pain.[16]

Honors and awards

[edit]

Dr Gobbi is a fellow of the American College of Neuropsychopharmacology and President-elect of the International College of Neuropsychopharmacology [17]

  • 2022 Canadian College of Neuropsychopharmacology (CCNP), Innovation in Neuropsychopharmacology[18]
  • 2022 International College of Neuropsychopharmacology (CINP) - Sumimoto/Sunovion Brain Health Basic Research Award[19]
  • 2020 McGill Principal's prize for public engagement through media[20]
  • 2017 Dr. Samarthji Lal award for Mental Health Research, Graham Boeckh Foundation[21]    
  • 2015 Premio Venezia - Italian Chamber of Commerce in Canada[22]
  • 2014 American College Neuropsychopharmacology (ACNP), Associate Member
  • 2013 Gold Medal for Merit- City of Osimo (An), Italy[23]
  • 2012 Canadian College of Neuropsychopharmacology (CCNP), Award for a young investigator[24]
  • 2007 Canadian Psychiatric Research Foundation (CPRF), Award for a young investigator[24]
  • 2006 Canadian Psychiatric Research Foundation (CPRF), Award for a young investigator[24]
  • 1998 Award for young researcher, World Federation of Societies of Biological Psychiatry[24]
  • 1998 Recipient of the Wyeth-Ayerst Canada Fellowship[24]
  • 1996 Award for research in Adolescent Psychiatry and Psychotherapy, Pio Sodalizio dei Piceni ,

Selected academic publications

[edit]
  • Gobbi, G., Bambico, F. R., Mangieri, R., Bortolato, M., Campolongo, P., Solinas, M., ... & Piomelli, D. (2005). Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proceedings of the National Academy of Sciences, 102(51), 18620-18625.
  • Gobbi, G., Atkin, T., Zytynski, T., Wang, S., Askari, S., Boruff, J., ... & Mayo, N. (2019). Association of cannabis use in adolescence and risk of depression, anxiety, and suicidality in young adulthood: a systematic review and meta-analysis. JAMA psychiatry, 76(4), 426-434.
  • Comai, S., & Gobbi, G. (2014). CCNP Award Paper: Unveiling the role of melatonin MT2 receptors in sleep, anxiety and other neuropsychiatric diseases: a novel target in psychopharmacology. Journal of Psychiatry and Neuroscience, 39(1), 6-21.
  • Posa, Luca, Danilo De Gregorio, Gabriella Gobbi, and Stefano Comai. "Targeting melatonin MT2 receptors: a novel pharmacological avenue for inflammatory and neuropathic pain." Current medicinal chemistry 25, no. 32 (2018): 3866-3882.
  • Lopez-Canul, M., Palazzo, E., Dominguez-Lopez, S., Luongo, L., Lacoste, B., Comai, S., ... & Gobbi, G. (2015). Selective melatonin MT2 receptor ligands relieve neuropathic pain through modulation of brainstem descending antinociceptive pathways. Pain, 156(2), 305-317.
  • De Gregorio, D., Popic, J., Enns, J. P., Inserra, A., Skalecka, A., Markopoulos, A., ... & Gobbi, G. (2021). Lysergic acid diethylamide (LSD) promotes social behavior through mTORC1 in the excitatory neurotransmission. Proceedings of the National Academy of Sciences, 118(5), e2020705118.
  • De Gregorio, D., Inserra, A., Enns, J. P., Markopoulos, A., Pileggi, M., El Rahimy, Y., ... & Gobbi, G. (2022). Repeated lysergic acid diethylamide (LSD) reverses stress-induced anxiety-like behavior, cortical synaptogenesis deficits and serotonergic neurotransmission decline. Neuropsychopharmacology, 47(6), 1188-1198.
  • Aguilar-Valles, A., De Gregorio, D., Matta-Camacho, E., Eslamizade, M. J., Khlaifia, A., Skaleka, A., ... & Sonenberg, N. (2021). Antidepressant actions of ketamine engage cell-specific translation via eIF4E. Nature, 590(7845), 315-319.

References

[edit]
  1. ^ a b "Dr. Gabriella Gobbi's Lab: Background".
  2. ^ a b "Gabriella Gobbi".
  3. ^ Wolfe, Lowell. "When it comes to drugs, McGill is still stuck in the past | McGill Tribune". www.mcgilltribune.com. Retrieved 2022-06-04.
  4. ^ "Nine Canada Research Chairs awarded to McGill". McGill Reporter. 2022-06-02. Retrieved 2022-06-04.
  5. ^ "LSD, a future antianxiety pill?". McGill University Health Centre. Retrieved 2022-06-04.
  6. ^ De Gregorio, Danilo; Popic, Jelena; Enns, Justine P.; Inserra, Antonio; Skalecka, Agnieszka; Markopoulos, Athanasios; Posa, Luca; Lopez-Canul, Martha; Qianzi, He; Lafferty, Christopher K.; Britt, Jonathan P. (2021-02-02). "Lysergic acid diethylamide (LSD) promotes social behavior through mTORC1 in the excitatory neurotransmission". Proceedings of the National Academy of Sciences. 118 (5): e2020705118. doi:10.1073/pnas.2020705118. ISSN 0027-8424. PMC 7865169. PMID 33495318.
  7. ^ "Tripping over the potential of psychedelics for autism". Spectrum | Autism Research News. 2022-05-31. Retrieved 2022-06-04.
  8. ^ "LSD may offer viable treatment for certain mental disorders".
  9. ^ Bambico, Francis Rodriguez; Nguyen, Nhu-Tram; Katz, Noam; Gobbi, Gabriella (March 2010). "Chronic exposure to cannabinoids during adolescence but not during adulthood impairs emotional behaviour and monoaminergic neurotransmission". Neurobiology of Disease. 37 (3): 641–655. doi:10.1016/j.nbd.2009.11.020. ISSN 0969-9961. PMID 19969082. S2CID 44645230.
  10. ^ De Gregorio, Danilo; Dean Conway, Joshua; Canul, Martha-Lopez; Posa, Luca; Bambico, Francis Rodriguez; Gobbi, Gabriella (2020-07-29). "Effects of Chronic Exposure to Low-Dose delta-9-Tetrahydrocannabinol in Adolescence and Adulthood on Serotonin/Norepinephrine Neurotransmission and Emotional Behavior". International Journal of Neuropsychopharmacology. 23 (11): 751–761. doi:10.1093/ijnp/pyaa058. ISSN 1461-1457. PMC 7745253. PMID 32725198.
  11. ^ "'Double-edged sword:' Teens' long-term cannabis use tied to higher depression risk". CBC News. 13 February 2019.
  12. ^ "Celebrating McGill researchers who are changing the world". McGill Reporter. 2020-04-28. Retrieved 2022-06-04.
  13. ^ Gobbi, Gabriella; Comai, Stefano (2019-03-01). "Differential Function of Melatonin MT1 and MT2 Receptors in REM and NREM Sleep". Frontiers in Endocrinology. 10: 87. doi:10.3389/fendo.2019.00087. ISSN 1664-2392. PMC 6407453. PMID 30881340.
  14. ^ Comai, Stefano; Ochoa-Sanchez, Rafael; Gobbi, Gabriella (April 2013). "Sleep–wake characterization of double MT1/MT2 receptor knockout mice and comparison with MT1 and MT2 receptor knockout mice". Behavioural Brain Research. 243: 231–238. doi:10.1016/j.bbr.2013.01.008. ISSN 0166-4328. PMID 23333399. S2CID 7363091.
  15. ^ Ochoa-Sanchez, R.; Comai, S.; Lacoste, B.; Bambico, F. R.; Dominguez-Lopez, S.; Spadoni, G.; Rivara, S.; Bedini, A.; Angeloni, D.; Fraschini, F.; Mor, M.; Tarzia, G.; Descarries, L.; Gobbi, G. (2011-12-14). "Promotion of Non-Rapid Eye Movement Sleep and Activation of Reticular Thalamic Neurons by a Novel MT2 Melatonin Receptor Ligand". Journal of Neuroscience. 31 (50): 18439–18452. doi:10.1523/jneurosci.2676-11.2011. ISSN 0270-6474. PMC 6623882. PMID 22171046.
  16. ^ Lopez-Canul, Martha; Palazzo, Enza; Dominguez-Lopez, Sergio; Luongo, Livio; Lacoste, Baptiste; Comai, Stefano; Angeloni, Debora; Fraschini, Franco; Boccella, Serena; Spadoni, Gilberto; Bedini, Annalida; Tarzia, Giorgio; Maione, Sabatino; Granados-Soto, Vinicio; Gobbi, Gabriella (February 2015). "Selective melatonin MT2 receptor ligands relieve neuropathic pain through modulation of brainstem descending antinociceptive pathways". Pain. 156 (2): 305–317. doi:10.1097/01.j.pain.0000460311.71572.5f. hdl:11576/2623398. ISSN 0304-3959. PMID 25599452. S2CID 25927444.
  17. ^ "CINP Home". cinp.org. Retrieved 2024-09-05.
  18. ^ Association, Canadian Medical (2022-05-17). "Canadian College of Neuropsychopharmacology 2022 award winners". Journal of Psychiatry and Neuroscience. 47 (3): E196. doi:10.1503/jpn.220082. ISSN 1180-4882. PMC 9188797. PMID 35580895.
  19. ^ "Gabriella Gobbi honoured by the International College of Neuropsychopharmacology". Health e-News. 2022-09-22. Retrieved 2023-01-20.
  20. ^ "Congratulations to Dr. Gabriella Gobbi, recipient of the Principal's Prize for Public Engagement through Media". Channels. Retrieved 2023-01-20.
  21. ^ Dr. Gabriella Gobbi, 2017 Recipient of the Dr. Samarthji Lal Award, retrieved 2023-01-20
  22. ^ "Premio Venezia - ICCC". ICCC. Retrieved 2023-01-20.
  23. ^ "5 TORRI - Ottobre 2013 by Comune di Osimo - Issuu". issuu.com. Retrieved 2023-01-20.
  24. ^ a b c d e "Biographical Sketch". Neurobiological Psychiatry Unit. Retrieved 2023-01-20.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Gabriella_Gobbi&oldid=1244222586"